Video

Dr. Langmuir on Vandetanib in Medullary Thyroid Cancer

Author(s):

Peter Langmuir, MD

Peter Langmuir, MD, Executive Director, Medical Science AstraZeneca on Vandetanib in Medullary Thyroid Cancer

Related Videos
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Timothy Yap, MBBS, PhD, FRCP
Related Content
FDA
May 29th 2024

FDA Grants Accelerated Approval to Selpercatinib for Pediatric RET+ Metastatic Thyroid Cancer or Solid Tumors

OncLive On Air
March 18th 2024

Revisit the OncLive On Air Episodes From February 2024

Jameel Muzaffar, MD, clinical director, head and neck medical oncology program, Duke Cancer Institute; instructor, Department of Medicine, Duke University School of Medicine
May 20th 2024

Tivumecirnon Plus Pembrolizumab Displays Activity and Tolerability in HNSCC

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer
September 2nd 2021

Sosa Talks Risk Factors, Rising Incidence, and Controversies in Thyroid Cancer

Versamune HPV + Pembro in HNSCC ©Lars Neumann- stock.adobe.com
May 10th 2024

First-Line Versamune HPV Plus Pembrolizumab Meets BOR End Point in Recurrent/Metastatic HPV16+ HNSCC

Kevin Harrington, BSc, MBBS, MRCP, FRCR, FRCP, PhD, DIC
May 7th 2024

Setanaxib Plus Pembrolizumab Improves Survival in Recurrent/Metastatic HNSCC